Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells
Sorafenib is the first-line recommended therapy for patients with advanced hepatocarcinoma (HCC) in de-differentiation stage (presenting epithelial−mesenchymal transition, EMT). We studied the role of the thioredoxin system (Trx1/TrxR1) in the sensitivity or resistance of HCC cells to the...
Main Authors: | María José López-Grueso, Raúl González, Jordi Muntané, José Antonio Bárcena, C. Alicia Padilla |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-10-01
|
Series: | Antioxidants |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3921/8/10/501 |
Similar Items
-
Pravastatin inhibits cell proliferation and increased MAT1A expression in hepatocarcinoma cells and in vivo models
by: Hijona Elizabeth, et al.
Published: (2012-02-01) -
Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer
by: Raúl González, et al.
Published: (2020-07-01) -
Effect of <i>Allium senescens</i> Extract on Sorafenib Resistance in Hepatocarcinoma Cells
by: Sohyeon Park, et al.
Published: (2021-04-01) -
Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells
by: Silvia Zappavigna, et al.
Published: (2019-05-01) -
Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery
by: Sebastien Benizri, et al.
Published: (2018-01-01)